The effect of Octreotide and somatostatin in adjuvant therapy of non biliary acute moderate and severe pancreatitis and its influence on inflammatory mediators
WANG Xuwei ZHANG Fubin LI Jun ZHANG Zunqi ZHANG Shiteng
Department of Emergency, PLA 105 Hospital, Anhui Province, Hefei 230031, China
Abstract：Objective To compare the efficacy of Octreotide and somatostatin in adjuvant therapy of non biliary acute moderate and severe pancreatitis and its influence on inflammatory mediators. Methods One hundred and eighteen cases of non biliary acute moderate and severe pancreatitis treated in PLA 105 Hospital from October 2015 to March 2017 were selected as research objects and divided into group A (61 cases) and group B (57 cases) according to random number table method. On the basis of routine treatment, group A and B were treated with Octreotide and somatostatin respectively for 7 days, and the recovery time of clinical indices, efficacy and complications of the two groups were compared. Results The recovery time on abdominal pain, fever, white blood cell count, serum amylase and the mean hospitalization time between the two groups had no significant differences (P ＞ 0.05). After treatment for 7 days, the differences on decreased acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) scores of the two groups were not statistically significant (P ＞ 0.05). The overall efficacy of the two groups had no significant difference (P ＞ 0.05); the decreased values of the two groups on tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-8, high-sensitivity C-reactive protein (hs-CRP) showed no statistically significant difference (P ＞ 0.05). The incidence of pancreatic pseudocyst, pulmonary infection, gastrointestinal bleeding, respiratory failure, flatulence in the two groups had no significant differences (P ＞ 0.05). Group A had a lower hypoglycemia rate than that of group B (P ＜ 0.05). Conclusion Octreotide and somatostatin in adjuvant therapy of non biliary acute moderate and severe pancreatitis has similar efficacy, both can significantly reduce inflammatory mediators, but hypoglycemia incidence is higher than that of somatostatin treatment.
王绪卫 章福彬 李俊 张尊祺 张世腾. 奥曲肽与生长抑素辅助治疗非胆源性急性中重症胰腺炎的效果及对炎性介质的影响[J]. 中国医药导报, 2018, 15(18): 116-119.
WANG Xuwei ZHANG Fubin LI Jun ZHANG Zunqi ZHANG Shiteng. The effect of Octreotide and somatostatin in adjuvant therapy of non biliary acute moderate and severe pancreatitis and its influence on inflammatory mediators. 中国医药导报, 2018, 15(18): 116-119.
2018, Vol. 15 
京公网安备 11010502046598号